{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:32:10Z","timestamp":1793550730271,"version":"4.5.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease. Several studies have reported outcomes of Janus kinase (JAK) inhibitors for treating AA, but limited evidence has emerged.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the effectiveness and safety associated with JAK inhibitors for AA.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>MEDLINE, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) were searched from inception until August 2022.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Only randomized clinical trials (RCTs) were included. Pairs of reviewers independently and in duplicate selected the studies.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Hartung-Knapp-Sidik-Jonkman random-effects models were used for meta-analysis. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcomes of interest were (1) proportion of patients who achieved 30%, 50%, and 90% improvement in Severity of Alopecia Tool (SALT) score from baseline, (2) change from baseline SALT score, and (3) treatment-related adverse event (AE).<\/jats:p><\/jats:sec>Results<\/jats:title>Seven RCTs with 1710 patients (1083 females [63.3%]; mean [SD] age range, 36.3 [10.4] to 69.7 [16.2] years) were eligible and included in the study. JAK inhibitors were associated with more patients achieving 50% improvement (odds ratio [OR], 5.28 [95% CI, 1.69-16.46]; GRADE assessment: low certainty) and 90% improvement (OR, 8.15 [95% CI, 4.42-15.03]; GRADE assessment: low certainty) in SALT score from baseline compared with placebo. JAK inhibitors were associated with more lowered SALT scores from the baseline compared with placebo (mean difference [MD], \u201334.52 [95% CI, \u221237.80 to \u221231.24]; GRADE assessment: moderate certainty), and JAK inhibitors were not associated with more treatment-related AEs (relative risk [RR], 1.25 [95% CI, 1.00-1.57]; GRADE assessment: high certainty) compared with placebo. High certainty of evidence showed that JAK inhibitors may not be associated with more severe AEs compared with placebo (RR, 0.77; 95% CI, 0.41-1.43). The subgroup analysis showed that oral JAK inhibitors were more efficient than placebo (change from baseline SALT scores: MD, \u201336.80; 95% CI, \u221239.57 to \u221234.02), and no difference was found between external JAK inhibitors and placebo (change from baseline SALT scores: MD, \u20130.40; 95% CI, \u221211.30 to 10.50).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of this systematic review and meta-analysis suggest that JAK inhibitors, compared with placebo, were associated with hair regrowth and that the outcome of oral JAK inhibitors was better than the external route of administration. Although the safety and tolerability of JAK inhibitors were acceptable, longer RCTs are needed to further assess the effectiveness and safety of these treatments for AA.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.20351","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T15:36:56Z","timestamp":1687880216000},"page":"e2320351","source":"Crossref","is-referenced-by-count":58,"title":["Janus Kinase Inhibitors for Alopecia Areata"],"prefix":"10.1001","volume":"6","author":[{"given":"Ming","family":"Liu","sequence":"first","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Gao","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Gansu Provincial Central Hospital, Lanzhou, China"},{"name":"Department of Dermatology, Gansu Provincial Maternity and Child-care Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyi","family":"Shen","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Gansu Provincial Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China"},{"name":"Key Laboratory of Evidence-based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"zoi230605r1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata.","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"zoi230605r2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"zoi230605r3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142205","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"issue":"14","key":"zoi230605r4","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.3390\/ijms21145137","article-title":"The effect of JAK inhibitor on the survival, anagen re-entry, and hair follicle immune privilege restoration in human dermal papilla cells.","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"zoi230605r5","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.jid.2018.05.027","article-title":"JAK inhibitors for treatment of alopecia areata.","volume":"138","author":"Wang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"zoi230605r6","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/DDDT","article-title":"Role of janus kinase inhibitors in the treatment of alopecia areata.","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"zoi230605r7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jaad.2021.02.071","article-title":"Alopecia areata flare patterns in children and young adults while on systemic tofacitinib.","volume":"86","author":"McKenzie","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"zoi230605r8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/pde.v39.1","article-title":"Oral tofacitinib for the treatment of alopecia areata in pediatric patients.","volume":"39","author":"Kibbie","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"zoi230605r9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.2019.33.issue-5","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis.","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"zoi230605r10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"71","key":"zoi230605r11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"zoi230605r13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method.","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"zoi230605r14","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/(ISSN)1097-0258","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"issue":"7650","key":"zoi230605r15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"zoi230605r16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2013study limitations (risk of bias).","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"zoi230605r17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2013imprecision.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"zoi230605r18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence\u2013indirectness.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"zoi230605r19","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2013inconsistency.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"zoi230605r20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2013publication bias.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi230605r21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"zoi230605r22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study.","volume":"82","author":"Olsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"zoi230605r23","article-title":"A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.","author":"Mikhaylov","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"zoi230605r24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"zoi230605r25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study.","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"zoi230605r26","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata.","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi230605r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis.","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"zoi230605r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104157","article-title":"Olumniant (baricitinib) oral tablets: an insight into FDA-approved systemic treatment for alopecia areata.","volume":"80","author":"Ali","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"2","key":"zoi230605r29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.2019.60.issue-2","article-title":"Treatment of alopecia areata: an Australian expert consensus statement.","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"issue":"2","key":"zoi230605r30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-020-00673-w","article-title":"Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.","volume":"21","author":"Sterkens","year":"2021","journal-title":"Clin Exp Med"},{"key":"zoi230605r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106962","article-title":"Should studies with no events in both arms be excluded in evidence synthesis?","volume":"122","author":"Xu","year":"2022","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"zoi230605r32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40779-021-00331-6","article-title":"Meta-analysis with zero-event studies: a comparative study with application to COVID-19 data.","volume":"8","author":"Wei","year":"2021","journal-title":"Mil Med Res"},{"issue":"5","key":"zoi230605r33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.25259\/IJDVL","article-title":"Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis.","volume":"87","author":"Yu","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"zoi230605r34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies.","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi230605r35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdv.v34.1","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.","volume":"34","author":"Guo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"zoi230605r36","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v32.5","article-title":"The role of janus kinase inhibitors in the treatment of alopecia areata: a systematic review.","volume":"32","author":"de Oliveira","year":"2019","journal-title":"Dermatol Ther"},{"key":"zoi230605r37","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.4536","article-title":"Comparative efficacy and safety of janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis.","volume":"103","author":"Barati Sedeh","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"zoi230605r38","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","article-title":"Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review.","volume":"11","author":"Mostaghimi","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"zoi230605r12","unstructured":"Guyatt? GH, Busse? JW. Modification of Cochrane tool to assess risk of bias in randomized trials. Accessed April 29, 2022. https:\/\/www.distillersr.com\/resources\/methodological-resources\/tool-to-assess-risk-of-bias-in-randomized-controlled-trials-distillersr"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2806418\/liu_2023_oi_230605_1686766004.00669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T15:37:00Z","timestamp":1687880220000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2806418"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.20351","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}